This site is intended only for healthcare professionals resident in Egypt




Sign InLog Out Our medicinesTherapy areasExplore contentExplore contentEventsDownloadable materialsVideosLet’s connectLet's ConnectContact usAsk a questionPfizer medical information



Burden of Disease Prevenar 13® Effectiveness Dosing Risk Prevention Important Safety Information Abbreviated Prescribing Information
Risk Prevention

Highest rates of IPD were found in children aged <12 months or >36 months.2

  • The risk of mortality increases with underlying comorbidities in older children and adolescents1
Objective and Method:
A nested case-control study to examine the association between asthma and invasive pneumococcal disease was conducted. The study population included persons 2 to 49 years of age who were enrolled in Tennessee Medicaid program (TennCare) for more than one year during the study period (1995 through 2002) and who resided in counties participating in a prospective laboratory-based program of surveillance for invasive pneumococcal disease. Result was evaluated at 95% CI.3
The PCV approved for children 5 to 17 years of age1
  • Children 5 to 17 years of age may receive a single dose of Prevenar 13® if they have been previously vaccinated with one or more doses of Prevenar 13®.1
Immune responses elicited by a single dose of Prevenar 13® is noninferior to Prevenar for the 7 common serotypes.1
  • In an open-label study in 592 healthy children and adolescents including those with asthma (17.4%) who may be predisposed to pneumococcal infection, Prevenar 13® elicited immune responses to all 13 serotypes.1 
  • In both the children 5 to 10 years of age and children and adolescents aged 10 to 17years, the immune response to Prevenar 13® was non inferior to Prevenar for the 7 common serotypes.1
Most commonly reported adverse events in children 6 weeks through 17 years:1 

Tenderness, redness or swelling at the injection site, irritability, decreased appetite, poor quality sleep and fever


PCV, pneumococcal conjugate vaccine.

  1. Egyptian drug authority Prevenar 13 leaflet approval date 7/4/2021, revision date November 2020.
  2. Picazo J, et al. Relationship between serotypes, age, and clinical presentation of invasive pneumococcal disease in Madrid, Spain, after introduction of the 7-valent pneumococcal conjugate vaccine into the vaccination calendar. Clin Vaccine Immunol. 2011;18(1):89-94.
  3. Talbot TR, et al. Asthma as a risk factor for invasive pneumococcal disease. N Engl J Med. 2005;352(20):2082-2090.

Explore More

Effectiveness in Pneumonia Learn MoreLoading
Effectiveness in IPD
Learn moreLoading
Effectiveness in Otitis Media
Learn moreLoading
Prevenar 13® Prescribing Information Loading

Adverse events should be reported. Adverse events can be reported to [email protected]

PfizerPro AccountPfizerPro Account

To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.

Sign inRegisterAccountSign Out

The product information provided in this site is intended only for Healthcare Professionals of Egypt. The products discussed herein may have different product labeling in different countries. 


Copyright © 2023 Pfizer biopharmaceutical LLC. All rights reserved.


For Healthcare Professionals only

These pages are not intended for patients or members of the general public. This portal contains healthcare promotional content.

If you select ‘No’, you will be redirected to, the global Pfizer website.

I confirm that I am a healthcare professional resident in Egypt.


Yes No
You are leaving the Pfizer for Professionals website
You are being directed to a third-party website:

This link is provided for your convenience. Please note that this third-party website is not controlled by Pfizer for Professionals or subject to our privacy policy.